paracetamol baxter 10 mg/ ml
baxter holding b.v. - paracetamol - infusjonsvæske, oppløsning - 10 mg/ ml
clopidogrel/acetylsalicylic acid teva
teva pharma b.v. - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - kombinasjoner - clopidogrel / acetylsalicylsyre teva er indisert for forebygging av atherotrombotiske hendelser hos voksne pasienter som allerede tar både klopidogrel og acetylsalisylsyre (asa). clopidogrel/acetylsalisylsyre teva er en fast dose kombinasjon legemiddel for videreføring av behandling i:ikke‑st-segment elevasjon akutt koronar syndrom (ustabil angina eller non‑q‑bølge myocardial infarction) inkludert pasienter som gjennomgår en stent plassering etter perkutan koronar interventionst segment elevasjon akutte myocardial infarction i medisinsk behandlede pasienter kvalifisert for trombolytisk behandling.
clopidogrel/acetylsalicylic acid zentiva (previously duocover)
sanofi-aventis groupe - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - antithrombotic agents - akutt koronar syndromemyocardial infarction.
acetylsalisylsyre actavis 75 mg
actavis group ptc ehf - acetylsalisylsyre - enterotablett - 75 mg
acetylsalisylsyre actavis 160 mg
actavis group ptc ehf - acetylsalisylsyre - enterotablett - 160 mg
acetylsalisylsyre norfri 500 mg
evolan pharma ab - acetylsalisylsyre - tablett - 500 mg
leuprorelinacetat aurora medical 3.75 mg
2care4 aps - leuprorelinacetat - pulver og væske til injeksjonsvæske, suspensjon i tokammersprøyte - 3.75 mg
leuprorelinacetat aurora medical 11.25 mg
2care4 aps - leuprorelinacetat - pulver og væske til injeksjonsvæske, suspensjon i tokammersprøyte - 11.25 mg
dolerin 500 mg / 150 mg
vale pharmaceuticals limited - paracetamol / ibuprofen - tablett, filmdrasjert - 500 mg / 150 mg
abiraterone accord
accord healthcare s.l.u. - abirateronacetat - prostata neoplasmer - endokrin terapi - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.